GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for the SION-451 + SION-2222 dual combination in the first quarter of 2027.
The open-label AscenSION CF trial will evaluate participants homozygous for F508del who switch from Trikafta to the dual combination over 28 days, assessing sweat chloride, safety, & pharmacokinetics.
SION-719 will not be advanced as an add-on to standard of care after the PreciSION CF trial failed its key activity endpoint, though post hoc analyses suggest NBD1 biological activity may have been blunted by confounding factors.
Clinical & nonclinical data presented at the 2026 North American Cystic Fibrosis Conference support the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF.
In September 2026, the company implemented a workforce reduction of approximately 46% & other cost-saving measures to focus resources on the SION-451 + SION-2222 program.
Research & development expenses reached $22.0 million for the third quarter of 2026, while general & administrative expenses totaled $12.8 million, both increases driven by restructuring & personnel costs.
The company reported a net loss of $32.4 million for the quarter ended September 30, 2026, compared to $20.3 million in the same period of 2025.
Cash, cash equivalents, & marketable securities totaled $249.8 million as of September 30, 2026, providing a runway to fund operations into the second half of 2029.